Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q4 FY2023 Earnings Presentation
74 slides from Metropolis Healthcare's earnings presentation, May 16, 2023
Slide 1: Intimation of Investor Presentation (exchange cover letter)
Ref: MHL/Sec&Legal/2023-24/11 Date: May 16, 2023 To, To, Head, Listing Compliance Department Head, Listing Compliance Department, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1. G Block, Dalal Street, Mumbai – 400 001. Bandra – Kurla Com
Slide 2: Reaching Out Responsibly - Investor Presentation May 2023
Reaching Out RESPONSIBLY Investor Presentation – May 2023
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q4FY23 Performance
Q4FY23 Performance...
Slide 5: FY23 Performance Snapshot
FY23 Performance Snapshot Total Revenue Rs. 1,148 Crores -7% YoY Revenue (Excl. Covid PCR & Core Business Revenue Covid Allied tests) Rs. 949 Crores Rs. 1,104 Crores 15% YoY 18% YoY Core Business Volume Volume (Excl. Covid PCR 21.2 Mn & Allied Tests) 13% YoY 24.5 Mn (excl. Covid & Covid 19% YoY Alli
Slide 6: Q4FY23 Performance Snapshot
Q4FY23 Performance Snapshot Total Revenue Rs. 283 Crores -8% YoY Revenue (Excl. Covid PCR & Core Business Revenue Covid Allied tests) Rs. 245 Crores Rs. 276 Crores 15% YoY 9% YoY Core Business Volume Volume (Excl. Covid PCR 5.3 Mn & Allied Tests) 15% YoY 6.1 Mn (excl. Covid & Covid 12% YoY Allied, P
Slide 7: Q4 FY23 Key Operational & Financial Highlights
Q4 FY23 Key Operational & Financial Highlights EBIDTA before Network Expansion for Dilution of ~120 bps is on account of Network expansion undertaken after April 01 Q4FY23 stood @ 26.9%* 2022. New Network has contributed ~4% of Revenues for Q4FY23. Core Business Revenue growth Core Business Revenue
Slide 8: EBITDA before Network Expansion for Q4FY23 at 26.9%
1. EBIDTA before Network Expansion for Q4FY23 stood @ 26.9%* Avg. Margins (Pre-Covid) ~27.0% EBIDTA Margin Analysis (Pre-Covid v/s Current) 26.8% 27.0% 27.1% 27.0% 1.1% 25.5% -1.2% -0.4% -0.4% -0.6% Margins dilution of ~150 bps majorly due to network expansion to fuel the future growth FY18 FY19 FY2
Slide 9: Core Business Revenue growth @ 15% for Q4FY23
2a. Core Business Revenue growth @ 15% for Q4FY23 Core Business (excl. PPP PPP Contracts* Covid PCR & Covid Allied Hi-Tech Diagnostics Total Revenues Contracts) +15% +7% -56% -87% -8% 245 17 53 24 306 22 283 Q4FY23 213 7 7 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Core Bu
Slide 10: Core Business Revenue growth – On a growth Trajectory
2b. Core Business Revenue growth @ 15% for Q4FY23 – On a growth Trajectory Non-Covid Revenues Non-Covid Revenues Q1FY22 v/s Q1FY23 Q2FY22 v/s Q2FY23 Core Revenue growth @ 15% for FY23 +21% +13% 224 244 217 184 Key Highlights ✓ Non-Covid revenues (excl. PPP & Hitech) for Q4FY23 stood at Rs. 245 crs a
Slide 11: Core Business Volume growth @ 15% for Q4FY23
3. Core Business Volume growth @ 15% for Q4FY23 No. of Patient Visits (In Mn.) Revenue Per Patient (In Rs.) +19.5% -0.4% -1.6% Marginal drop in RPP 11.5 950 946 972 957 on account of PPP 9.7 contract closure. Excl. +9.8% PPP, RPP grew by 1% 2.7 2.9 for FY23 & was flat for Q4FY23 Q4FY22 Q4FY23 FY22 F
Slide 12: Q4FY23 Premium Wellness grew @ 43%
4a. Q4FY23 Premium Wellness grew @ 43% Population for Diagnostic Industry Total Premium Wellness Revenue (excl. Covid & Allied) 45% 6% 106 94% 73 43% 37 26 Wellness Population Illness Population Q4FY22 Q4FY23 FY22 FY23 ✓ Revenue from Premium Wellness has grown by 43% on Y-o-Y Our focus is to cater t
Slide 13: Premium Wellness at 15% of total contribution
4b. Q4FY23 Premium Wellness grew @ 43% and stood at 15% of total contribution Our Brand Equity across markets & Doctors Trust and Reliance on Metropolis helps us grow our Specialized & Premium Wellness segment faster than the Industry growth Q4FY22 Q4FY23 Q4FY22 Q4FY23 Revenue excl. Covid PCR & Covi
Slide 14: B2C revenue growth @ 17% – Mumbai B2C grew 18%
5a. B2C revenue growth @ 17% for Q4FY23 – Mumbai B2C revenue grew by 18% Total B2C Revenue B2C revenue growth for Q4FY23 in Mumbai grew by 18% & Pune grew 23% on account of our strong brand presence & dense network 16.6% 19.5% Despite intense competition Metropolis was able to Key Highlights increas
Slide 15: B2C share of business ~50% in FY23
5b. B2C revenue growth @ 17% - Overall Share of B2C Business ~50% in FY23 B2C Revenue Contribution (Non-Covid Business) (Rs. in Crs.) Our B2C includes revenue from Home visit & walk-in at Our & Franchise Centers, it does not include B2B collection done by Franchise B2C 49% Ratio 41% 42% 44% 47% Cent
Slide 16: Non-Covid Revenues from North up by 30%
6a. Non-Covid Revenues from North up by 30% Revenue for North grew by ~30% for Q4FY23 on Y-o-Y basis Volume growth for North Revenue per Test for Opened 5 new Labs in stood at 25% for Q4FY23 North grew by 5% for North to expand on Y-o-Y basis Q4FY23 on Y-o-Y basis geographical reach B2B revenue grew
Slide 17: Network Strategy
Network Strategy Laboratory Network - MHL Service Network - MHL Hitech Network Total Network Rationalization ARC Period Lab network Service network +548 Centers Third Party PSCs Total 175 Total 3,675 + 14 labs Laboratory Network Owned PSCs 3,612 20 Labs 20 63 155 3,064 754 141 2,731 119 124 125 2,55
Slide 18: Diversified Revenue contribution across Geographies (1/2)
Diversified Revenue contribution across Geographies (1/2)… Continue to focus on strengthening the Brand in Focus cities through increase in B2C share while improving the share of Seeding and Other cities through a healthy mix of B2B and B2C driven by our large Test menu Q4FY22 Q4FY23 Q4FY22 Q4FY23 R
Slide 19: Diversified Revenue contribution across Geographies (2/2)
Diversified Revenue contribution across Geographies (2/2)… Revenue Mix between Geographies Q4FY22 Q4FY23 Q4FY22 Q4FY23 Total Revenue Revenue Excl. Covid PCR & Covid Allied tests 7% 6% 8% 7% 6% 8% 6% 6% 31% 31% 32% 32% 51% 51% 51% 50% 4% 4% 4% 4% North South East West International ✓ Revenues in Nort
Slide 20: Creating a Digital Transformation for business to grow
Creating a Digital Transformation for business to grow Enhanced Plans Benefits Productivity • A Fully Scaled Application Programming • Digital Leadership Rapid Scalability Interface (API) - Centric Tech Core • Full-fledged Customer Relationship • Faster go-to-market Management (CRM) stack for Servic
Slide 21: Metropolis – Certified Great Place to Work
Metropolis – Certified Great Place to Work Metropolis is the First Indian Diagnostic Organization for getting Great Place To Work certification. EMPLOYEE BRAND- Our Identity Attributes that Build Our Culture Trust, Openness, Innovation, Compassion & Growth Mindset Communicate Amplify with Talent Com
Slide 22: Metropolis ESG Journey
Metropolis ESG Journey Well identified ESG Focus Areas and assessments ESG Initiatives in FY 22-23 ESG Roadmap for FY 23-24 are created as per the materiality matrix based on Focus on Energy Conservation, Water and Waste Management. the GRI, SASB and SDG Frameworks. Full BSSR Stepped into our missio
Slide 23: CSR at Metropolis
CSR at Metropolis Too Shy to Ask (TSTA) MedEngage Preventive health Care Project DSEU*( Delhi Skills Outreach and Digital Program Programme Entrepreneurial University) • Metropolis Foundation, the CSR • The annual MedEngage Scholarship • Under the CSR intiiatives, • DSEU has collaborated with arm of
Slide 24: Steady Focus on Balance Sheet continues
Steady Focus on Balance Sheet continues Debtor Days Working Capital Days 31 Key Highlights 30 14 14 ✓ Debtor days as on Mar-23 has reduced to 30 days as compared to 31 days as on Mar- 22 ✓ Cash & Cash Equivalents dropped on Mar-22 Mar-23 account of prepayment of loan taken for Mar-22 Mar-23 acquisit
Slide 25: Q4 & FY23 Consolidated Profit & Loss Statement
Q4 & FY23 Consolidated Profit & Loss Statement Profit & Loss Statement (Rs. Crs.) Q4FY23 Q4FY22 Y-o-Y FY23 FY22 Y-o-Y Total Revenue from Operations 282.5 305.9 -7.6% 1148.2 1228.3 -6.5% EBIDTA (before CSR & ESOP) 72.5 82.2 -11.8% 304.4 361.6 -15.8% EBIDTA (before CSR & ESOP) Margin 25.7% 26.9% 26.5%
Slide 26: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Crs.) Mar-23 Mar-22 Equity & Liabilities (Rs. Crs.) Mar-23 Mar-22 Non-current assets 1,198.8 1,137.1 Equity 990.8 888.2 Property, Plant and Equipment 137.2 139.2 Equity Share capital 10.2 10.2 ROU Assets 173.4 109.5 Other equity 978.0 876.0 Goodwill 454.7 454.7
Slide 27: Consolidated Abridged Cash Flow Statement
Consolidated Abridged Cash Flow Statetment Cash Flow Statement (Rs. Crs) FY23 FY22 Profit Before Tax 187.5 293.4 Adjustments for Depreciation and other items 104.1 58.8 Operating profit before working capital changes 291.6 352.2 Changes in working capital 7.1 -16.4 Cash generated from operations 298
Slide 28: Metropolis is well placed
Metropolis is well placed
Slide 29: Doctor recommendation, not price, is key determinant for acute patients
Doctor recommendation & not price is the key determinant for acute patients % of respondents (top 4 criteria) Doc recommendation and not price is Acute Patients are highly influenced by doctors the major determinant of acute uptake 100% 62% 55% 51% 57% 90% Metro Cities 43% 40% 36% 30% 27% 22% 20% 80
Slide 30: Metropolis is well placed
Metropolis is well placed Category Acute Patient Chronic Patient Preventive Customers Doctor Influence Highest Moderate Lowest Price Factor Lowest Moderate Highest Online aggregators Lowest Moderate Highest Impact ✓ Appx. 18% of the volumes at ✓ Appx. 2% of the volumes at ✓ Appx. 80% of the volumes
Slide 31: Mumbai continues to be a key market for us
Mumbai continues to be a key market for us Service Network in Mumbai Mumbai is a key market for Metropolis with strong doctor & customer connect +116 ✓ Centres in Mumbai continue to be highly 457 profitable even after increasing competition in the city +59 341 +12 +18 ✓ Expect strong profitability i
Slide 32: Strong Productivity from new centres in focus cities
Strong Productivity from new centres in focus cities Service Network in Focus Cities Strong expansion plan across focus cities ✓ Focus cities for Metropolis include Mumbai, +144 Pune, Chennai, Bengaluru & Surat 800 +130 ✓ Productivity for new centers in its first 12 656 +24 months continue to increa
Slide 33: Way forward
Way forward...
Slide 34: Way Forward
Way Forward… Added 14 labs & 531 network centers in FY23 of planned addition of 90 labs and 1,800 Network Expansion network centers by FY25 to strengthen our leadership position in existing geographies and build Metropolis brand in new geographies Added 100+ locations for home testing in FY22. Will
Slide 35: Network Expansion Plan
1. Network Expansion Plan Metropolis Network Expansion Plan Laboratory Network Service Network +72% +70% 215 4,355 90 1,800 125 2,555 FY21 FY25E FY21 FY25E ✓ Expand to existing & newer locations – Aim to expand the service network to existing locations to strengthen our leadership position as Benefi
Slide 36: Driving growth via digitally driven, asset-light home-visit segment
2. Driving growth via digitally driven, asset-light home-visit segment Digital demand generation Asset Light Rapid scale up via technology drive processes + 3rd party network Integrated CRM to Captured via provide omni- Metropolis website Capturing Changing Demand channel support and app 1 Covid has
Slide 37: Deepening our digital touch points, capability throughout value chain
3. Deepening our digital touch points, capability throughout our value chain Digitally engaging Scaling up Digitizing distribution & logistics: Digital Customer Engagement: customers and operational Launched Unified Patient Launching an end-to-end online partners capabilities Information System lead
Slide 38: Levers for Margin Improvement & Cost Efficiencies
4. Levers for Margin Improvement & Cost Efficiencies Increased Utilization and Product Mix Higher utilization of Labs and increase in patient visits coupled with superior product mix 01 Increased Home Visits Cost Efficiency Initiatives Increase Home Visits revenue with focused Encouraging innovation
Slide 39: Hitech Integration
5. Hitech Integration Hitech Diagnostic Centre Revenue strategy to aid double digit growth Revenue Rs. (In Crs.) ✓ Dual brand strategy in Chennai while single brand in rest of Covid Non-Covid TN & Karnataka. Plan to launch 100 centers in FY23 +15% 124 123 ✓ Increasing contribution of speciality test
Slide 40: Overview
Overview
Slide 41: We are Metropolis: The Pathology Specialist
We are Metropolis: The Pathology Specialist To be a respected healthcare brand trusted by clinicians, patients and stakeholders. Positively impact lives of patients Vision in their most anxious times and turn their anxiety in to assurance. Helping people stay healthy, by accurately revealing their 4
Slide 42: Journey to Leadership Position
Journey to Leadership Position ✓ First Referral Laboratory Set- ✓ Ameera Shah takes charge ✓ Secondary transaction by ✓ Exit of Warburg Pincus, ✓ Strong Thrust on Retail up by Founder & Chairman Dr. Foxcreek Investment Limited management control by frontend Expansion ✓ First major acquisition - Sush
Slide 43: Three decades of Delivering Value to Stakeholders
Three decades of Delivering Value to Stakeholders Leadership Position Across Industry METROPOLIS Focus Area ACCREDITATION CUSTOMER & QUALITY EXPERIENCE ROCE SPECIALITY SCORES SCORE BUSINESS INCREASED INFRASTRUCTURE PRODUCTIVITY REVENUE PER REALISATION PER TEST MENU OF YOUNG PATIENT PATIENT NETWORK 4
Slide 44: Key Drivers for Growth
Key Drivers for Growth 01 Industry Growth 05 Expansion Plan 02 Value Chain 06 Quality 03 Business Model 07 People 04 Service Network 08 Digital Transformation 43
Slide 45: Diagnostic Industry Poised to grow
1a. Diagnostic Industry Poised to grow… Indian Healthcare Industry Size of Indian Diagnostics Market Indian Diagnostics Industry Breakup Source – IIFL Diagnostics Report (in Billion Rs.) 6.0% +11.6% 924 9.0% 4.0% Healthcare Delivery - Hospitals 776 42% Pharma Pathology +16.4% 596 13.0% Medical Devic
Slide 46: Top players to continue to acquire market share of standalone centers
1b. Top players to continue to acquire market share of standalone centers Brand Awareness Increased brand awareness amongst patients and customers towards quality, reliability and test accuracy Service + Scale Large Test menu Large Test menu by organized diagnostics chains Factors leading Consolidat
Slide 47: Presence in key pockets of Value Chain
2.Presence in key pockets of Value Chain Diagnostic Industry - Fragmented Routine Test Metropolis Focus Highly Fragmented Market Low Quality Standard Majority Diagnostic Players Technician + Run Lab Low on Technical Qualifications & Moderate Competition Presence across Accreditations (99.9% labs rem
Slide 48: Hub & Spoke Model to scale efficiently
3. Hub & Spoke Model to scale efficiently Home Collection Global Reference Lab (GRL) Individual Patient (B2C) Wholesale (B2B) RRL / Satellite Lab Express Lab Third Party Lab / Hospitals / ARCs Collection Patient Centres Patient Leverage Widespread Delivery to our Enhances Collection of Greater netwo
Slide 49: Patient Centric Network
4.Patient Centric Network Global and More than ~4,000 Present in 20 States 40+ Years National Over 10,000 Patient Test’s & Profiles & 220 cities Quality Touch Points of Credible Operations Accreditations Why Metropolis ? Collection ✓ Conclusive Diagnosis with Large Centres Pics test Menu backed by H
Slide 50: Asset Lite Expansion Plan
5. Asset Lite Expansion Plan Asset Light Model Network Expansion Strategy Doctor APSC/ Lab on ✓ Focus on Asset Light Model to achieve Geographic Expansion with Bleeding DAPSC Lease High Scalability Point (DBP) ✓ The A-PSC and D-APSC Model allows us to grow our revenues by providing management and br
Slide 51: Quality in Core
6a. Quality in Core Quality Scores of 98.5% in 2018-19 by College Quality protocols following global standards of American Pathology 99.9% of industry labs remain un-accredited with lack of minimum standards in the industry Large Investments in Focus on Governance Information and rigorous audit Tech
Slide 52: Globally Compliant Quality Standards
6b. Globally Compliant Quality Standards “Global Lab Accreditations” No. of Audits Conducted by PAC Team FY 19-20 20-21 21-22 22-23 1,057 583 988 1,907 ✓ PAC Team: Special Pre Analytical Care Team constituted as part of the Quality Assurance Team ✓ This team conducts thorough internal audits as per
Slide 53: Scientific brand leadership
6c. Scientific brand leadership Segment Focus ◼ New tests on advanced technologies ddPCR, LCMS, New tests, R&D Strategy CGH Array and WSI Women & Child health • Gynecxpert ◼ NGS R&D Innovation Pipeline • Neoxpert • Pediamet ◼ Companion Diagnostics CDx Integrated Oncopathology • Oncomet ◼ Artificial
Slide 54: People are our greatest asset
7. People are our greatest asset Leadership Team Investment in future leaders aligned to vision of the company. across levels and ahead of time. 2. Decision making Business models at par with changes 1. Leadership and Strengthening Structures to in the fields of Technology & structure support object
Slide 55: Leveraging IT for Competitive Advantage
8. Leveraging IT for Competitive Advantage 1 2 3 4 Improving Business revenue Improved Operational Improve Customer Cost Saving & Optimization generation capabilities Efficiency Experience ✓ Zero Data Loss; 100% data ✓ IBM Watson Campaign Automation replication in remote location ✓ Mobility Applicat
Slide 56: Digital Transformation to improve efficiency
8a. Digital Transformation to improve efficiency 1 Standardization Achieve standardization across 2 Reduced Errors Reduce incidence of errors due to human intervention our operations Patients & Customers 3 Technical Operations Provide convenience to our 5 Monitor Technical Operations patients and cu
Slide 57: Future Strategy
Future Strategy 01 Increase Services 02 Increase Scale 56
Slide 58: Customer Centricity: In everything we do
Customer Centricity: In everything we do 01 02 03 04 Easy to Interpret Test Sample Collection from Conclusive Diagnosis Digital Access Report Doorstep We also have a policy of ensuring We have developed a Mobile Conclusive Diagnosis to our Application We offer our patients a Detailed We have increas
Slide 59: Sustainable Growth across Network
Sustainable Growth across Network Network of 210 Cities Criteria Strategy % of Revenue for FY23 (Total Business) ✓ Increasing productivity of Collection Centers ✓ Enhancing our Laboratory Capacity and Test Menu by adding Latest Machines and Technology ✓ High Potential Market Focus Cities ✓ Expanding
Slide 60: Increase B2C sales mix
Focus on Profitable B2C Business Increase B2C sales mix Deeper Network Strengthen Productivity of Wellness initiatives Penetration Metropolis Brand existing young network for consumers Deeper centre penetration Expand Branded third- Increase number of referring Creating an easy and engaging in Focus
Slide 61: Growing Inorganically – A Win-Win Strategy
Growing Inorganically– A Win-Win Strategy Build Industry Best practices Introducing Standardized Machines and SOPs in a phased manner resulting in efficiency and quality enhancement Access to Metropolis Network Providing acquired entities access to Metropolis Sales and Marketing Network to improve t
Slide 62: Successful Track Record of Inorganic Strategy: 24 Acquisitions in 18 years
Successful Track Record of Inorganic Strategy : 24 Acquisitions in 18 years Revenue at the time of Few of the Acquired Companies Year of Acquisition Location Revenue for FY22 acquisition Sudharma Metropolis Health Services 2003 Kerala Rs. 1.8 Crores Rs. 58.9 Crores Private Limited Golwilkar Metropol
Slide 63: Plenty of Opportunities for Growth
Plenty of Opportunities for Growth… Growing our offering of Test Packages to Increase Revenue Test Packages Metrics. Customized packages to Institutional Customers Expansion and Personalized Packages to Individual Patients are key Leverage our vast capabilities in Molecular Diagnostics, Aggressive N
Slide 64: Historical Financial & Operational Performance
Historical Financial & Operational Performance
Slide 65: Better than industry growth
Better than industry growth Revenue (In Rs. Crs.) Bolstering Growth in Wellness Segment Metropolis Wellness revenue contribution for +12% 1,229 1,148 Metropolis is 12% in FY23 998 856 760 644 This market is expected to grow at a CAGR of 20% over next 3 financial years (Frost & Sullivan) FY18 FY19 FY
Slide 66: Growing B2C Mix
Growing B2C Mix Retail contribution in Focus Cities (Non-Covid) to Total Revenue 58% 60% 60% 56% 52% 48% Efforts to increase the Retail share in focus cities to 65% FY18 FY19 FY20 FY21 FY22 FY23 Chart shows B2C contribution over the years in focus cities; Mumbai, Chennai, Bangalore, Surat and Pune T
Slide 67: Financial Highlights
Financial Highlights Revenue (In Rs. Crs.) Normalized EBITDA (In Rs. Crs.) Normalized EBITDA (%) 1,228 1,148 362 998 301 304 30.2% 856 29.4% 760 27.3% 27.3% 26.5% 232 207 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Reported PAT (In Rs. Crs.) ROCE (%)* ROE (%)* 43.1% 29
Slide 68: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 FY18 Revenue from Operations 1148.2 1,228.3 997.8 855.5 760.1 643.6 Cost of Material Consumed 253.3 276.1 252.2 204.1 173.5 145.9 Laboratory testing charges 6.6 6.9 5.4 6.9 5.6 5.7 Gross Profit 888.4 945.3 740.1 6
Slide 69: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity & Liabilities (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Non-current assets 1,198.8 1,137.1 396.0 355.2 247.9 230.1 Equity 990.8 888.2 708.1 525.2 420.0 429.1 Property, Plant and Equipment 137.2 1
Slide 70: Board of Directors and Management Team
Board of Directors and Management Team
Slide 71: Board of Directors
Board of Directors Dr. Sushil Kanubhai Shah Ameera Sushil Shah Chairman & Executive Director Managing Director Holds a bachelor’s degree in Medicine and Surgery and Holds a bachelor’s degree in Business Administration a degree of Doctor of Medicine in Pathology and from the University of Texas and a
Slide 72: Management Team
Management Team Ameera Sushil Shah Mr. Surendran Chemmenkotil Managing Director Chief Executive Officer Holds a bachelor’s degree in Business Administration from Over 34 years of rich and diverse experience across the University of Texas and also completed Owner-President consumer facing companies s
Slide 73: Recent Awards and Accolades
Recent Awards and Accolades Period Particulars Our MD Ms. Ameera Shah honoured with the Most Powerful Woman in Business Award by Business Today and also has been Mar-23 recognized as the “Most Influential Women in Healthcare” by Business World. Our CFO Mr. Rakesh Agarwal honoured with the Top 100 CF
Slide 74: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Rakesh Agarwal - CFO Mr. Shogun Jain / Mr. Sagar Shroff Email Id – rakesh.agarwal@metropolisindi
Metropolis Healthcare — Q4 FY2023 Earnings Presentation on 6ix